SODIUM BICARBONATE- sodium bicarbonate injection
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
For treatment of metabolic acidosis. See package insert for specific indications.
Each mL contains:
Sodium Bicarbonate……………………..84 mg
(equal to 1 mEq/mL)
Water for Injection………………………q.s.
Administer intravenously. See package insert for complete directions for use and dosage information.
Clipper Distributing Company, LLC.
St. Joseph, MO 64507
Trademarks are the property of
Clipper Distributing Company, LLC
Take Time Observe Label Directions
Nova-Tech, Inc. Grand Island, NE 68801
for Neogen Corporation.
Store at temperatures between 15°and 30°C (59°-86°F).
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
FOR ANIMAL USE ONLY
KEEP OUT OF REACH OF CHILDREN
This is a sterile single dose vial. No preservatives have been added. Discard unused portion after use. Do not use if solution is hazy, cloudy, or contains a precipitate. The total osmolar concentration of this package is approximately 2000 mOsm/L.
SODIUM BICARBONATE 8.4%
STERILE NONPYROGENIC SOLUTION
FOR VETERINARY USE ONLY
DESCRIPTION: Sodium Bicarbonate 8.4% is a sterile
nonpyrogenic preparation of sodium bicarbonate
(NaHCO3) in Water for Injection. Each 100 mL contains
8.4 grams of sodium bicarbonate (100 mEq/100 mL
each of sodium and bicarbonate). This concentrated
solution has an approximate pH of 7.8.
ACTIONS: Sodium Bicarbonate is useful in the
treatment of metabolic acidosis due to a wide variety of
causes. Sodium Bicarbonate therapy increases plasma
bicarbonate, buffers excess hydrogen ion concentration,
raises blood pH and reverses the clinical manifestations
of acidosis. Sodium Bicarbonate also alkalinizes the
INDICATIONS: Sodium Bicarbonate is indicated in the
treatment of metabolic acidosis which may be due to
severe renal disease, uncontrolled diabetes, circulatory
insufficiency due to shock or severe dehydration,
cardiac arrest and severe primary lactic acidosis.
Sodium Bicarbonate is also indicated in severe diarrhea
which is often accompanied by a significant loss of
bicarbonate. Sodium Bicarbonate 8.4% is indicated in
the treatment of metabolic acidosis in cattle, horses,
sheep, swine and dogs depending upon causative
CONTRAINDICATIONS: Sodium Bicarbonate is contraindicated
in animals losing chloride by vomiting and in
animals receiving diuretics known to produce a
PRECAUTIONS: Bicarbonate therapy is directed at
producing a substantial correction of low total CO2
content and blood pH, but risks of overdosage and
alkalosis should be avoided. Repeated fractional doses
and periodic monitoring by appropriate laboratory tests
are therefore recommended to minimize the possibility
of overdosage. Sodium Bicarbonate addition to
parenteral solutions containing calcium should be
avoided except where compatibility has been previously
established. Precipitation or haze may result from
sodium bicarbonate-calcium admixtures, and the
resulting solution should not be administered.
DOSAGE AND ADMINISTRATION: Sodium Bicarbonate
8.4% is injected intravenously. Caution should be taken
in emergencies where very rapid infusion of large
quantities of bicarbonate is indicated, such as cardiac
arrest. Sodium Bicarbonate solutions are hypertonic
and may produce an undesirable rise in plasma sodium
concentration during the process of correction of
metabolic acidosis. During cardiac arrest, however, the
risks from acidosis exceed those of hypernatremia. In
cattle and horses, 200 to 300 mL of 8.4% solution may
be given undiluted by rapid infusion using a needle and
Sodium Bicarbonate 8.4% solution is often added to other
intravenous fluids for the less urgent forms of metabolic
acidosis. The amount of bicarbonate to be given over a
4 to 8 hour period is approximately 2 to 5 mEq per kg of
body weight (1-2.5 mL/lb body weight) depending upon
the severity of the acidosis as judged by the lowering of
total CO2 content, blood pH and clinical condition of the
Bicarbonate therapy should always be planned in
stepwise fashion since the degree of response from a
given dose is not precisely predictable. Initially, an
infusion of 2 to 5 mEq per kg of body weight over a
period of 4 to 8 hours will produce a measurable
improvement in the abnormal acid-base status of the
blood. Completion of therapy is dependent upon the
clinical response of the animal. If severe symptoms
have abated, then frequency of administration and size
of the dose should be reduced.
OVERDOSAGES: In case alkalosis occurs, the
bicarbonate should be stopped and the animal
managed according to the degree of alkalosis present.
Sodium chloride injection (0.9%) may be given intravenously;
potassium chloride also may be indicated if
there is hypokalemia. Severe alkalosis may be accompanied
by hyperirritability or tetany, and these
symptoms may be controlled by calcium gluconate. An
acidifying agent such as ammonium chloride may also
be indicated in severe alkalosis.
HOW SUPPLIED: Sodium Bicarbonate 8.4% is
supplied in a 100 mL single dose vial.
WARNING: This is a sterile single dose vial. No preservatives
have been added. Discard unused portion after
use. Do not use if solution is hazy, cloudy or contains a
Store at a temperature between 15°-30° C (59°-86° F).
CAUTION: Federal law (U.S.A.) restricts this drug to
use by or on the order of a licensed veterinarian.
RMS# 92-516 NTI# 18-9078Neogen
944 Nandino Blvd
Lexington, KY 40511
859-254-1221 or 800-525-2022
|SODIUM BICARBONATE sodium bicarbonate injection|
|Labeler — Phoenix (150711039)|
|Registrant — Nova-Tech, Inc (196078976)|
Revised: 11/2019 Phoenix
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.